People: CTi Biopharma Corp (CTIC.A)

CTIC.A on American Stock Exchange

2.42USD
3:44pm EST
Price Change (% chg)

$0.06 (+2.54%)
Prev Close
$2.36
Open
$2.35
Day's High
$2.45
Day's Low
$2.35
Volume
20,603
Avg. Vol
4,652
52-wk High
$4.24
52-wk Low
$1.71

Search Stocks

Summary

Name Age Since Current Position

Phillip Nudelman

78 2005 Independent Chairman of the Board

James Bianco

57 2012 President, Chief Executive Officer, Director

Louis Bianco

61 2013 Executive Vice President, Finance and Administration, and Chief Governance Officer

Jack Singer

71 2013 Interim Chief Medical Officer, Executive Vice President, Global Medical Affairs and Translational Medicine, and Chief Compliance Officer.

Matthew Plunkett

42 2012 Executive Vice President, Corporate Development

Nancy Boman

Senior Vice President of Clinical Development and Regulatory Affairs

Monique Greer

47 Senior Vice President of Corporate Communications and Investor Relations

Karen Ignagni

60 2014 Director

John Bauer

73 2005 Independent Director

Vartan Gregorian

79 2001 Independent Director

Richard Love

70 2007 Independent Director

Mary Mundinger

76 1997 Independent Director

Frederick Telling

62 2006 Independent Director

Reed Tuckson

2011 Independent Director

Ed Bell

Director - Investor Relations

Biographies

Name Description

Phillip Nudelman

Dr. Phillip M. Nudelman, Ph.D., is Independent Chairman of the Board of CTI BioPharma Corp. From 2000 to 2007, he served as the President and Chief Executive Officer of The Hope Heart Institute and continued to serve as a member of the board of directors for Hope Heart Institute until 2010. From 1998 to 2000, he was the Chairman of the board of Kaiser/Group Health, retiring in 2000 as Chief Executive Officer Emeritus. From 1990 to 2000, Dr. Nudelman was the President and Chief Executive Officer of Group Health Cooperative of Puget Sound, a health maintenance organization. He also currently serves on the board of directors of OptiStor Technologies, Inc. and Zynchros, Inc. Dr. Nudelman served on the White House Task Force for Health Care Reform from 1992 to 1994 and the President’s advisory Commission on Consumer Protection and Quality in Health Care from 1996 to 1998. He has also served on the Pew Health Professions Commission and the AMA Task Force on Ethics, the Woodstock Ethics Commission, and currently serves as Chairman of the American Association of Health Plans. Dr. Nudelman received his B.S. degree in microbiology, zoology and pharmacy from the University of Washington, and holds an M.B.A. and a Ph.D. in health systems management from Pacific Western University.

James Bianco

Dr. James A. Bianco, M.D., has served as President, Chief Executive Officer, Director of CTI BioPharma Corp., since July 25, 2012. He is the company's principal founder and served as the company's President and Chief Executive Officer and director from February 1992 to July 2008. With the addition of Craig W. Philips as President in August 2008, Dr. Bianco now serves as the company's Chief Executive Officer and director. Prior to founding the Company, Dr. Bianco was an assistant professor of medicine at the University of Washington, Seattle, and an assistant member in the clinical research division of the Fred Hutchinson Cancer Research Center. From 1990 to 1992, Dr. Bianco was the director of the Bone Marrow Transplant Program at the Veterans Administration Medical Center in Seattle. Dr. Bianco currently serves on the board of directors of the Seattle Police Foundation. Dr. Bianco received his B.S. degree in biology and physics from New York University and his M.D. from Mount Sinai School of Medicine.

Louis Bianco

Mr. Louis A. Bianco is Executive Vice President, Finance and Administration, and Chief Governance Officer of CTI BioPharma Corp. He was also a director from the company's inception in September 1991 to April 1992 and from April 1993 to April 1995. From January 1989 through January 1992, Mr. Bianco was a Vice President at Deutsche Bank Capital Corporation in charge of risk management. Mr. Bianco is a Certified Public Accountant and received his M.B.A. from New York University.

Jack Singer

Dr. Jack W. Singer, M.D., is Interim Chief Medical Officer, Executive Vice President, Global Medical Affairs and Translational Medicine, and Chief Compliance Officer of CTI BioPharma Corp. Dr. Singer has been one of our directors since our inception in September 1991. From July 1995 to January 2004, Dr. Singer was our Executive Vice President, Research Program Chairman and from April 1992 to July 1995, he served as our Executive Vice President, Research and Development. Prior to joining us, Dr. Singer was a professor of medicine at the University of Washington and a full member of the Fred Hutchinson Cancer Research Center. From 1975 to 1992, Dr. Singer was the Chief of Medical Oncology at the Veterans Administration Medical Center in Seattle. Dr. Singer received his M.D. from State University of New York, Downstate Medical College.

Matthew Plunkett

Dr. Matthew J. Plunkett, Ph.D., is Executive Vice President, Corporate Development of CTI BioPharma Corp., since September 4, 2012. He previously served as Managing Director and Head of West Coast Biotechnology for Oppenheimer & Co. and its United States predecessor, CIBC World Markets. Dr. Plunkett has more than 15 years experience in the biopharmaceutical industry. He previously served as Chief Financial Officer at the California Institute for Regenerative Medicine and as Vice President and Chief Financial Officer at iPierian. He began his scientific career at Sunesis Pharmaceuticals and Axys Advanced Technologies. He obtained a Bachelor of Science Degree in Chemistry from Harvey Mudd College, Claremont, California, and a Doctorate in Philosophy in Organic Chemistry from University of California, Berkeley.

Nancy Boman

Monique Greer

Karen Ignagni

Ms. Karen Ignagni is Director of CTI BioPharma Corp. Since joining the organization in 1993, Ms. Ignagni has won many accolades for her leadership. AHIP was formed in late 2003 as a result of a merger of the American Association of Health Plans (AAHP) and Health Insurance Association of America (HIAA). Previously, she directed the AFL-CIO’s Department of Employee Benefits. In the 1980’s, she was a professional staff member on the U.S. Senate Labor and Human Resources Committee, preceded by work at the U.S. Department of Health and Human Services. Ms. Ignagni has authored more than 90 articles on a wide range of health care policy issues, and appears regularly before congressional committees and on national newscasts. She has served on numerous boards and advisory groups, including presently the Board of the National Quality Forum, the National Advisory Committee for Altarum Institute’s Center for Sustainable Health Spending and the Healthcare Financial Management Association’s Leadership Council.

John Bauer

Mr. John H. Bauer is Independent Director of CTI BioPharma Corp. Mr. Bauer serves as an executive advisor and Chief Financial Officer at DigiPen Institute of Technology. He was formerly Executive Vice President for Nintendo of America Inc. from 1994 to 2004. While at Nintendo of America Inc., he had direct responsibility for all administrative and finance functions. He has also served as a consultant to Nintendo of America Inc. From 1963 to 1994, he worked for Coopers & Lybrand, including serving as the business assurance (audit) practice partner. He was also a member of Coopers & Lybrand’s Firm Council, the senior policy making and governing board for the firm. Mr. Bauer is also a member of the board of directors of RIPL Corporation and Zones, Inc. Mr. Bauer received his B.S. degree in accounting from St Edward’s University.

Vartan Gregorian

Dr. Vartan Gregorian, Ph.D., has served as Independent Director of Cell Therapeutics Inc since December 28, 2001. He is the twelfth president of Carnegie Corporation of New York, a grant-making institution founded by Andrew Carnegie in 1911. Prior to his current position, which he assumed in June 1997, Dr. Gregorian served for eight years as Brown University’s sixteenth president. He was awarded a Ph.D. in history and humanities from Stanford University. A Phi Beta Kappa and a Ford Foundation Foreign Area Training Fellow, he is a recipient of numerous fellowships, including those from the John Simon Guggenheim Foundation, the American Council of Learned Societies, the Social Science Research Council, and the American Philosophical Society.

Richard Love

Mr. Richard L. Love is Independent Director of CTI BioPharma Corp., since September 21, 2007. Mr. Love is presently a manager of Translational Accelerators, LLC. Mr. Love is also a director of Applied Microarrays Inc., Ascalon, PAREXEL International, SalutarisMD Inc., was previously a director of ImaRx Therapeutics Inc., and, prior to its acquisition by the company in July 2007, served as chairman of the board of Systems Medicine, Inc. He started two biopharmaceutical companies, Triton Biosciences Inc. and ILEX Oncology Inc.; he served as chief executive officer for Triton Biosciences from 1983 to 1991, and as chief executive officer for ILEX Oncology 1994 to 2001. In addition, Mr. Love has served in executive positions at not-for-profit organizations, including the Cancer Therapy and Research Center, The San Antonio Technology Accelerator Initiative and the Translational Genomics Research Institute. Mr. Love obtained a Bachelor of Science and Master of Science degree in Chemical Engineering from Virginia Polytechnic Institute and State University.

Mary Mundinger

Dr. Mary O'Neil Mundinger has served as Independent Director of CTI BioPharma Corp., since April 1997. From 1986 to 2010, she was a dean and professor at the Columbia University School of Nursing, and an associate dean on the faculty of medicine at Columbia University. In July 2010, Dr. Mundinger was appointed the Edward M. Kennedy Professor in Health Policy and Dean Emeritus at the Columbia University School of Nursing. Dr. Mundinger has served on the board of directors of United Health Group and Gentiva Health Services and is an elected member of the Institute of Medicine of the National Academies, the American Academy of Nursing and the New York Academy of Medicine. Dr. Mundinger received her doctorate in public health from Columbia’s School of Public Health.

Frederick Telling

Dr. Frederick W. Telling, Ph.D., is Independent Director of CTI BioPharma Corp. Prior to his retirement in 2007, Dr. Telling was a corporate officer of Pfizer, most recently as Vice President of Corporate Policy and Strategic Management since 1994. He joined Pfizer in 1977 and was responsible for strategic planning and policy development throughout the majority of his career. He currently serves on the board of directors of Eisai N.A., Oragenics, Inc. and Aequus Biopharma, Inc., a subsidiary of the Company. Dr. Telling is also a member of the Committee for Economic Development, IBM’s Healthcare & Life Sciences Advisory Council, the EAA, and the United Hospital Fund and is a non-board emeritus at ORBIS. Dr. Telling received his B.A. degree from Hamilton College and his Masters of Industrial and Labor Relations and Ph.D. in Economics and Public Policy from Cornell University.

Reed Tuckson

Dr. Reed V. Tuckson, M. D., has served as Independent Director of CTI BioPharma Corp., since September 22, 2011. Dr. Tuckson is the Executive Vice President and Chief of Medical Affairs of UnitedHealth Group and has served in that capacity since December 2006. Prior to his position at UnitedHealth Group, from January 2006 to December 2006, Dr. Tuckson served as Senior Vice President, Professional Standards, for the American Medical Association. He has also served as President of the Charles R. Drew University of Medicine and Science in Los Angeles, Senior Vice President for Programs of the March of Dimes Birth Defects Foundation and Commissioner of Public Health for the District of Columbia. He currently serves on the board of directors of the Alliance for Health Reform, the American Telemedicine Association, the National Patient Advocate Foundation, Project Sunshine, and the Arnold P. Gold Foundation and the Advisory Committee to the Director of the National Institute of Health. Dr. Tuckson received his B.S. degree in Zoology from Howard University and his medical doctor degree from the Georgetown University School of Medicine, and completed the Hospital of the University of Pennsylvania’s General Internal Medicine Residency and Fellowship programs.

Ed Bell

Basic Compensation

Options Compensation

Search Stocks